Design development and evaluation of nanosuspensions for enhancement of bioavailability of poorly soluble drugs

Abstract

newline BCS class-II has poor bioavailability due to limited aqueous solubility. Candesartan cilexetil, telmisartan and ziprasidone hydrochloride were taken for research work. Nanosuspensions were developed to enhance oral bioavailability. Drugs and stabilizers were subjected to identification and compatibility study by FTIR and DSC. Based on solubility from different solvents, solvent and antisolvent were identified. Nanosuspensions were prepared using a precipitation-ultrasonication method and lyophilized using cryo-protectant. Various formulation as well as process parameters were screened by Plackett-Burman design to identify key factors producing maximum effect on nanosuspension. Such two factors were considered to optimize formulation by 32 factorial design. Optimized formulations were evaluated by various physicochemical parameters. Accelerated stability study was performed according to ICH guidelines. Bioavailability study was carried out to compare optimized nanosuspensions with available marketed preparations. The developed products exhibited improved bio-availability as compared to marketed formulations. newline